Sensei Biotherapeutics, Inc. (SNSE)

1.6500 +0.3800 (+29.92%) At close: 04:00PM EDT

Sensei Biotherapeutics, Inc.

1405 Research Boulevard
Suite 125
Rockville, MD 20850
United States
240 243 8000
https://www.senseibio.com

Sector(s): Healthcare
Industry: Biotechnology
Full Time Employees: 28

Key Executives

Name	Title	Pay	Exercised	Year Born
Mr. John K. Celebi M.B.A.	President, CEO & Director	799.69k	N/A	1972
Ms. Lora Pike	Vice President of Investor Relations & Communications	N/A	N/A	N/A
Mr. Christopher W. Gerry J.D.	Senior VP, General Counsel & Secretary	N/A	N/A	N/A
Dr. Aaron Weitzman FACP, M.D., Ph.D.	Chief Medical Officer	N/A	N/A	N/A

Amounts are as of December 31, 2022 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Sensei Biotherapeutics, Inc., an immuno-oncology company, engages in the discovery and development of therapeutics for cancer patients. The company's Tumor Microenvironment Activated Biologics platform is designed to generate highly selective therapeutics that disable immunosuppressive signals or activate immunostimulatory signals selectively in the tumor microenvironment. It also offers SNS-101, an active monoclonal antibody that is in clinical Phase 1/2 targeting the immune checkpoint VISTA for the treatment of solid tumors. The company's pipeline includes SNS-103 and SNS-102, an active monoclonal antibody, which are in early development stages for the treatment of solid tumors, as well as SNS-201 is a bispecific antibody targeting CD28. It has a collaboration with The University of Washington to conduct preclinical studies for its SNS-101 program. The company was formerly known as Panacea Pharmaceuticals, Inc. Sensei Biotherapeutics, Inc. was incorporated in 1999 and is headquartered in Rockville, Maryland.

Corporate Governance

Sensei Biotherapeutics, Inc.’s ISS Governance QualityScore as of May 1, 2024 is 9. The pillar scores are Audit: 9; Board: 7; Shareholder Rights: 10; Compensation: 9.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.